ABUS Stock Analysis: Buy, Sell, or Hold?
ABUS - Arbutus Biopharma Corporation Common Stock
$4.55
0.42 (10.17%)
▲
5d:
+11.52%
30d:
-5.41%
90d:
-5.99%
BUY
MODERATE Confidence
Last Updated: February 2, 2026
Earnings: Mar 26, 2026
Get Alerted When ABUS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
6 traders called ABUS this week
67% bullish • 2 bearish
67% bullish • 2 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ABUS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ABUS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ABUS is currently trading at $4.55, which is considered oversold relative to its 30-day fair value range of $4.25 to $4.82.
Technical Outlook: Technically, ABUS is showing sideways momentum. The price is approaching resistance at $4.60. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 10.2% recently.
Market Sentiment: ABUS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.81 (+40.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ABUS is showing sideways momentum. The price is approaching resistance at $4.60. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 10.2% recently.
Market Sentiment: ABUS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.81 (+40.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$4.25 -
$4.82
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+10.2%)
- BULLISH: Trading 40.7% below Wall St target ($5.81)
Fair Price Analysis
30-Day Fair Range
$4.25 -
$4.82
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$3.50
Resistance Level
$4.60
Current Trend
Sideways
Fundamental Context
Forward P/E (Next Year Est.)
-18.00
Wall Street Target
$5.81
(+40.7%)
Revenue Growth (YoY)
-60.5%
Profit Margin
-289.4%
Last updated: February 02, 2026 2:41 PM ET
Data refreshes hourly during market hours. Next update: 3:41 PM
Data refreshes hourly during market hours. Next update: 3:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABUS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 61 BUY |
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 57 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 59 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 61 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$140 | 52 HOLD |
